Chad

Effect of enhanced investment scenario*					
	Baseline 2011	Constant coverage scenario 2035	Enhanced investment scenario with R&D 2035	Events averted by enhanced investment in 2035	
Reproductive, maternal, newborn, and child health				**A**	**B**
Births	510	1,043	383	660	660
Total fertility rate	5.8	5.8	2.1	*	*
Maternal deaths	6	12	1	10	10
Stillbirths	16	32	4	28	15
Total under-5 child deaths	86	172	12	160	85
Under-5 mortality rate	168	165	31	*	*
Maternal mortality ratio	1,100	1,099	250	*	*
Tuberculosis					
New cases	17	20	6	14	14
Deaths	4	5	0	4	4
HIV/AIDS					
New infections	17	20	2	19	19
Deaths in people aged 5 years and over	10	14	3	11	11
Total deaths	**119**	**231**	**20**	**213**	**125**

***Effect of enhanced investment scenario**

For births, stillbirths, cases, deaths, and infections, the annual rate is in thousands. The results have been rounded. R&D=research and development. *Events averted in 2035 is defined as the difference between the constant coverage scenario in 2035 and the enhanced investment scenario with R&D in 2035 (ie, enhanced investment including scale up of new tools developed by R&D). Column A includes stillbirths and child deaths averted because a pregnancy was averted-ie, column A includes potential deaths among individuals who never existed. Column B excludes these deaths-ie, column B shows only deaths associated with pregnancies that did actually occur. The total fertility rate is expressed as the number of births expected per woman at the then-prevailing age-specific mortality and fertility rates. The under-5 mortality rate is defined as the probability of dying between birth and 5 years of age at the age-specific mortality rates of the indicated year (denoted by demographers as 5q0). The maternal mortality ratio is the number of women who die during pregnancy and childbirth, per 100,000 livebirths.

Incremental costs of enhanced investment scenario^					
Us $ million	Incremental costs 2015	Incremental costs 2025	Incremental costs 2035	Incremental costs 2016-2025	Incremental costs 2026-2035
Programmatic investment (scaling up current interventions)					
Family planning	1	8	23	41	155
Maternal and neonatal health	6	24	28	161	263
Immunization	1	-6	-24	-19	-146
Treatment of childhood illness	4	18	5	132	120
Malaria	46	71	108	588	898
Tuberculosis	10	8	10	83	89
HIV/AIDS	8	32	27	201	322
Subtotal	77	154	178	1,188	1,702
Health system strengthening					
Incremental investment	248	216	256	2,134	2,386
Programmatic investment (scaling up new tools)					
All new tools and interventions	22	25	29	222	273
Total investment	**346**	**395**	**462**	**3,544**	**4,361**
Ratios					
Cost per death averted ($)	6,450	2,773	2,190	3,426	2,408
Population (m)	13	17	19	151	181
Incremental cost per capita ($)	26.14	23.74	24.02	23.43	24.03

^Incremental costs of enhanced investment scenario

Population is total, not incremental. Treatment of childhood illness excludes malaria costs, TB costs exclude ART for HIV+ TB patients. Scale up of new products assumed to increase reduction in annual mortality and infection rates by incremental 2%.


Maternal Mortality Ratio
Maternal mortaly ratio (deaths per 100,000 livebirths)
1200
1000
800
600
400
200
0
2011
2015
2020
2025
2030
2035
Year
Constant Coverage
Enhanced Investment Scenario
Enhanced Investment Scenario with R&D
Convergence Target


Under-5 Mortality Rate
Under-5 mortality rate (deaths per 1,000 livebirths)
180
160
140
120
100
80
60
40
20
0
2011
2015
2020
2025
2030
2035
Year
Constant Coverage
Enhanced Investment Scenario
Enhanced Investment Scenario with R&D
Convergence Target


AIDS Death Rate
AIDS death rate (deaths per 100,000 persons)
100
90
80
70
60
50
40
30
20
10
0
2011
2015
2020
2025
2030
2035
Year
Constant Coverage
Enhanced Investment Scenario
Enhanced Investment Scenario with R&D
Convergence Target


TB Death Rate
TB death rate (deaths per 100,000 persons)
40
35
30
25
20
15
10
5
0
2011
2015
2020
2025
2030
2035
Year
Constant Coverage
Enhanced Investment Scenario
Enhanced Investment Scenario with R&D
Convergence Target